HOXA9 and prostate adenocarcinoma: Correlation analysis revealed that the reduced expression of HOXA9 in BRCA and KIRC patients resulted from promoter DNA hypermethylation, while the elevated expression in PRAD patients was attributed to promoter DNA hypomethylation (Supplementary Table 2).